Ionis Pharmaceuticals to Present New Hereditary Angioedema Drug Data

The company will showcase findings on its approved DAWNZERA treatment at the 2026 AAAAI Annual Meeting.

Published on Feb. 27, 2026

Got story updates? Submit your updates here. ›

Ionis Pharmaceuticals, Inc. announced it will present new data on DAWNZERA (donidalorsen), its approved RNA-targeted medicine for hereditary angioedema (HAE), at the 2026 American Academy of Allergy, Asthma & Immunology (AAAAI) Annual Meeting in Philadelphia. The data includes new analyses from the Phase 3 OASIS-HAE and OASISplus studies.

Why it matters

DAWNZERA is the first and only RNA-targeted medicine approved for the treatment of HAE, a rare and potentially life-threatening genetic disorder. The new data could provide further insights into the drug's efficacy and safety profile, which is important for healthcare providers and patients managing this chronic condition.

The details

The data Ionis plans to present will include new analyses from the Phase 3 OASIS-HAE and OASISplus studies of DAWNZERA. DAWNZERA is an RNA-targeted medicine that was approved in the U.S. and EU for the treatment of HAE.

  • The 2026 AAAAI Annual Meeting will take place in Philadelphia, PA.

The players

Ionis Pharmaceuticals, Inc.

A biopharmaceutical company focused on developing and commercializing RNA-targeted therapies.

DAWNZERA (donidalorsen)

Ionis' approved RNA-targeted medicine for the treatment of hereditary angioedema.

Got photos? Submit your photos here. ›

The takeaway

The presentation of new data on DAWNZERA at the AAAAI Annual Meeting demonstrates Ionis' commitment to advancing treatment options for patients with hereditary angioedema, a rare and debilitating condition.